The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
O-mel-sora: A national multicenter phase II trial of sorafenib in metastatic uveal melanoma.
Frédéric Mouriaux
No relevant relationships to disclose
Vincent Servois
No relevant relationships to disclose
Sophie Piperno-Neumann
No relevant relationships to disclose
Thierry Lesimple
No relevant relationships to disclose
Antoine Thyss
No relevant relationships to disclose
Thomas Jouary
No relevant relationships to disclose
Eve-Marie Neidhardt
No relevant relationships to disclose
Nicolas Penel
No relevant relationships to disclose
Corinne Delcambre
No relevant relationships to disclose
Jean-Jacques Parienti
No relevant relationships to disclose
Caroline Serre-Henry
No relevant relationships to disclose
Florence Joly
No relevant relationships to disclose